NCT00710086

Intravenous Remifentanil for Labor Analgesia

Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,000 (actual)
• Sponsor: Nanjing Medical University · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Labor analgesia is an essential health caring procedure for women. However, epidural analgesia cannot be performed on all subjects for different contraindications, such as lower platelet counter, back infection at the puncture site, and fear of epidural injection etc. Therefore, intravenous analgesia is an alternative for such conditions. Given the influence of intravenous administration of drugs on fetus, the drug selection is very important. Remifentanil, a super-short efficacious opioid, can last for 3-4 minutes after injection, which is similar in both maternal and fetal environment. Thus the fetus-associated side effects would be less than other drugs. The investigators hypothesized that remifentanil would be a superior intravenous drug used with patient-controlled technique for labor analgesia.

Conditions

• Labor Pain

Interventions

Type	Name	Description
DRUG	Hydromorphone	Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
DRUG	Remifentanil	Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2008-07-04
• Last updated: 2009-09-18

Locations

1 site across 1 country: China